Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Syntex/Chiron

Executive Summary

Research collaboration announced Sept, 8 will focus on the discovery and design of synthetic compounds that inhibit the interaction of cellular adhesion molecules (CAMs) such as selectins and integrins. Syntex will have exclusive worldwide rights to develop and market collaboratively discovered CAM inhibitors for inflammation, asthma, allergy and transplantation, and Chiron will have right to jointly discovered CAM inhibitors for infectious disease applications, oncology and ophthalmology. Each company will have the option to co-fund the other company's development program in return for profit sharing or royalties on the other company's sales.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS023312

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel